We recruited 1004 consecutive patients with lung adenocarcinomas regardless of initial stage and treatments, and tumor samples such as biopsy, surgical, or cytologic specimens were included if sufficient tissue were available for EGFR mutational analysis. The gene discussed is EGFR; the disease is neoplasm.